CD24 and hepatocellular carcinoma: Recent studies on CD24 depletion using siRNA and NDRG2 regulation in hepatocellular carcinoma [47, 71] and shRNA methods in bladder cancer [72] demonstrated the reduction of tumourigenesis and CD24 could be used as a prognostic marker.